XNCR / Xencor to Present Preclinical Data from XmAb® Cytokine Programs at the American Association for Cancer Research (AACR) Annual Meeting 2022

Xencor (XNCR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). more_horizontal

Xencor is expected to release data from a phase 2 study in early 2024 targeting patients with mCRPC and gynecological cancers, which could generate sh more_horizontal

Xencor, Inc. is a biotech company focused on the development and commercialization of anticancer medications. They have successful partnerships and li more_horizontal

Xencor, Inc. (NASDAQ:XNCR ) Q2 2023 Earnings Conference Call August 3, 2023 4:30 PM ET Company Participants Charles Liles - Head of Corporate Communic more_horizontal

Xencor (XNCR) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.91. This compares to loss of $0.57 more_horizontal

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytoki more_horizontal

Xencor (XNCR) came out with a quarterly loss of $1.02 per share versus the Zacks Consensus Estimate of a loss of $0.75. This compares to earnings of $ more_horizontal

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokin more_horizontal